-
Sinovac Partners with Colombia University to Boost Vaccine R&D
•
China’s Sinovac (NASDAQ: SVA) has announced a partnership with Universidad de Antioquia of Colombia (UdeA) to collaborate on the construction of a vaccine research and development (R&D) center. The collaboration aims to enhance technical exchanges on vaccines and novel therapies, as well as to conduct basic research and translational studies…
-
SeeNeuro Medical Raises RMB 100M in Series B Funding for Neural Regulation Devices
•
Hangzhou-based SeeNeuro Medical, a developer of implantable neural regulation devices, has reportedly raised RMB 100 million (USD 13.7 million) in a Series B financing round. The funding was led by SDIC Unity Capital, with participation from BioTrack Capital, a returning investor. The proceeds will be used to support new product…
-
MicuRx Pharmaceuticals Concludes US Phase I Study for MRX-8
•
Shanghai-based antibacterial drug developer MicuRx Pharmaceuticals (SHA: 688373) has announced the conclusion of Phase I of its first-in-human study for MRX-8, a new drug targeting gram-negative drug-resistant bacteria, in the United States. The results demonstrated that at the expected clinical dose, MRX-8 exhibited an acceptable safety and pharmacokinetic profile in…
-
Henlius Biotech’s Hanbeitai Approved for Hepatocellular Carcinoma
•
Shanghai Henlius Biotech Inc. (HKG: 2696) has announced receiving a fourth indication approval from the National Medical Products Administration (NMPA) for its bevacizumab biosimilar, Hanbeitai. The drug is now approved for the treatment of hepatocellular carcinoma (HCC), expanding its therapeutic applications in China. Previous Approvals and Therapeutic IndicationsHanbeitai was first…
-
Antengene’s Xpovio Receives Taiwan FDA Approval for Multiple Indications
•
China-based biopharma Antengene Corp., Ltd (HKG: 6996) has announced receiving market approval from the Taiwan Food and Drug Administration (TFDA) for its drug Xpovio (selinexor) in three indications. The approvals cover the treatment of adult patients with relapsed or refractory multiple myeloma (R/R MM) and relapsed or refractory diffuse large…
-
AIM Vaccine Receives CDE Approval for Serum-Free Rabies Vaccine Trial
•
China-based AIM Vaccine Co., Ltd (HKG: 6660) has announced receiving clinical trial approval from the Center for Drug Evaluation (CDE) for its investigational lyophilized human rabies vaccine (serum-free Vero cells). This approval marks a significant step forward in the company’s efforts to develop and commercialize innovative rabies vaccines. Vero Cells…
-
Rici Healthcare to Acquire Unicorn II Holdings for RMB 180M
•
China-based Rici Healthcare Holdings Limited (HKG: 1526), also known as Rich Healthcare, is set to acquire 1,672,140 shares of Unicorn II Holdings Limited for RMB 180 million (USD 24.7 million). The acquisition aims to strengthen Rici Healthcare’s position in the rapidly growing private medical services sector in China. Market Growth…
-
Roche Reports Q3 Sales Growth, Hit by COVID-19 Product Decline
•
Swiss pharmaceutical giant Roche (SWX: ROG) released its Q3 2022 financial report last week, showing group sales up 2% year-on-year (YOY) at constant exchange rates (CER) during the 9-month period to CHF 47.0 billion (USD 46.8 billion). The growth rates for Q1, Q2, and Q3 were +11%, +0%, and -6%…
